Improving Outcomes for Patients With Chronic Lymphocytic Leukemia

Mazyar Shadman, MD, MPH, and Amy Goodrich, CRNP, reviewed data regarding the mechanistic activity, efficacy, and safety of approved and emerging therapeutic options for chronic lymphocytic leukemia (CLL) and strategies for managing adverse events associated with approved therapies for CLL.

Detalles Bibliográficos
Autores principales: Shadman, Mazyar, Goodrich, Amy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2020
Materias:
Meeting Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857328/
https://www.ncbi.nlm.nih.gov/pubmed/33598332
http://dx.doi.org/10.6004/jadpro.2020.11.3.19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857328/
https://www.ncbi.nlm.nih.gov/pubmed/33598332
http://dx.doi.org/10.6004/jadpro.2020.11.3.19

Ejemplares similares